cabergoline has been researched along with cetrorelix in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aleyasin, A; Bahmaee, F; Hosseini, MA; Mahdavi, A; Safdarian, L | 1 |
| El Maghraby, HA; El-Gezary, D; Gaafar, S | 1 |
1 review(s) available for cabergoline and cetrorelix
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for cabergoline and cetrorelix
| Article | Year |
|---|---|
Treatment of ovarian hyperstimulation syndrome using gonadotropin releasing hormone antagonist: a pilot study.
Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Ovarian Hyperstimulation Syndrome; Pilot Projects; Young Adult | 2012 |
Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol.
Topics: Adult; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Female; Fertility Agents, Female; Gonadotropin-Releasing Hormone; Gonadotropins; Humans; Ovarian Hyperstimulation Syndrome; Polycystic Ovary Syndrome; Risk Factors; Sperm Injections, Intracytoplasmic; Young Adult | 2019 |